[go: up one dir, main page]

AR106369A1 - Uso prolongado de composiciones de silicato de circonio y métodos para su uso - Google Patents

Uso prolongado de composiciones de silicato de circonio y métodos para su uso

Info

Publication number
AR106369A1
AR106369A1 ARP160103150A ARP160103150A AR106369A1 AR 106369 A1 AR106369 A1 AR 106369A1 AR P160103150 A ARP160103150 A AR P160103150A AR P160103150 A ARP160103150 A AR P160103150A AR 106369 A1 AR106369 A1 AR 106369A1
Authority
AR
Argentina
Prior art keywords
methods
circonio
zirconium silicate
silicate compositions
prolonged
Prior art date
Application number
ARP160103150A
Other languages
English (en)
Inventor
F Guillem Alvaro
J Keyser Donald
Original Assignee
Zs Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58227650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR106369(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zs Pharma Inc filed Critical Zs Pharma Inc
Publication of AR106369A1 publication Critical patent/AR106369A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/02—Processes using inorganic exchangers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/14—Base exchange silicates, e.g. zeolites
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C01B39/02—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C01B39/02—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
    • C01B39/06—Preparation of isomorphous zeolites characterised by measures to replace the aluminium or silicon atoms in the lattice framework by atoms of other elements, i.e. by direct or secondary synthesis
    • C01B39/08—Preparation of isomorphous zeolites characterised by measures to replace the aluminium or silicon atoms in the lattice framework by atoms of other elements, i.e. by direct or secondary synthesis the aluminium atoms being wholly replaced
    • C01B39/085—Group IVB- metallosilicates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Geology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones de silicato de circonio que tienen un contenido de plomo menor que 0,6 ppm y métodos para fabricar silicato de circonio en volúmenes de reactor que superan 200-L con un contenido de plomo menor que 1,1 ppm. El contenido de plomo del silicato de circonio se encuentra dentro de los niveles que se consideran aceptables para el uso prolongado dados los requisitos de dosis para silicato de circonio.
ARP160103150A 2015-10-14 2016-10-14 Uso prolongado de composiciones de silicato de circonio y métodos para su uso AR106369A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/883,428 US9592253B1 (en) 2015-10-14 2015-10-14 Extended use zirconium silicate compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
AR106369A1 true AR106369A1 (es) 2018-01-10

Family

ID=58227650

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103150A AR106369A1 (es) 2015-10-14 2016-10-14 Uso prolongado de composiciones de silicato de circonio y métodos para su uso

Country Status (19)

Country Link
US (4) US9592253B1 (es)
EP (1) EP3362456A4 (es)
JP (1) JP6546700B2 (es)
KR (1) KR102667566B1 (es)
CN (2) CN108137620B (es)
AR (1) AR106369A1 (es)
AU (1) AU2016338753C1 (es)
CA (1) CA3000950C (es)
CL (1) CL2018000916A1 (es)
CR (1) CR20180276A (es)
EA (2) EA035890B1 (es)
HK (1) HK1254808A1 (es)
IL (1) IL258478B (es)
MX (1) MX2018004440A (es)
MY (1) MY187088A (es)
PH (1) PH12018500786B1 (es)
TW (1) TWI742004B (es)
WO (1) WO2017066128A1 (es)
ZA (1) ZA201803095B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013020533A2 (pt) 2011-02-11 2016-10-18 Zs Pharma Inc silicato de zircônio microporoso para o tratamento de hipercalemia
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
WO2019092179A1 (en) * 2017-11-10 2019-05-16 Sandoz Ag Pharmaceutical compositions comprising zs-9
EP3937953A1 (en) 2019-03-13 2022-01-19 Astrazeneca AB Potassium-binding agents for use in hemodialysis patients
CN117342570A (zh) * 2023-09-04 2024-01-05 杭州国瑞生物科技有限公司 一种环硅酸锆钠的a晶型及其制备方法
CN117735564B (zh) * 2023-12-19 2025-12-19 杭州国瑞生物科技有限公司 一种环硅酸锆钠的b晶型及其制备方法与应用
CN120172420B (zh) * 2025-03-21 2025-12-23 时森海(杭州)医药科技有限公司 控制粒径分布的环硅酸锆钠及其制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE21224E (en) 1939-10-03 Coherent zirconium silicates
US2809943A (en) * 1952-09-11 1957-10-15 Dow Chemical Co Weighted ion exchange resin granules and method of making same
US3492092A (en) * 1966-04-04 1970-01-27 Chem Separations Corp Ion exchange process for treating crude mineral solutions
US3947279A (en) 1971-12-23 1976-03-30 Owens-Illinois, Inc. Thermally crystallizable glasses possessing precision controlled crystallization and flow properties and process of producing same
US4581141A (en) 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
FR2444005A1 (fr) 1978-12-15 1980-07-11 Ugine Kuhlmann Procede industriel de fabrication en semi-continu de zeolithe a
US4943545A (en) 1987-06-08 1990-07-24 Mobil Oil Corporation Activation of zeolites
US5015453A (en) 1989-04-28 1991-05-14 W. R. Grace & Co.-Conn. Crystalline group IVA metal-containing molecular sieve compositions
US5338527A (en) 1992-08-20 1994-08-16 Uop Zirconium silicate composition, method of preparation and uses thereof
PL172190B1 (pl) 1992-10-28 1997-08-29 Crosfield Joseph & Sons Bezpostaciowa krzemionka i sposób wytwarzania bezpostaciowej krzemionki PL PL PL
US5518707A (en) 1994-10-24 1996-05-21 Uop Metallo germanates
IT1283284B1 (it) 1996-03-21 1998-04-16 Eniricerche Spa Zeolite ers-10 e procedimento per la sua preparazione
FR2750893B1 (fr) 1996-07-12 1998-10-30 Elf Aquitaine Procede de synthese de zeolithe avec agitation homogene du milieu, dispositif et application
US5891417A (en) 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
US5888472A (en) 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
CA2268888A1 (en) 1997-05-12 1998-11-19 Itsuki Uehara Separator for battery and alkali secondary battery using the same
US6007790A (en) 1998-08-13 1999-12-28 Uop Llc Family of microporous indium silicate compositions
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US6332985B1 (en) 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US7041274B2 (en) 1999-10-22 2006-05-09 Intevep, S.A. Aluminosilicate compositions, preparation and use
US20020061521A1 (en) 2000-01-31 2002-05-23 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6379641B1 (en) 2000-05-01 2002-04-30 Uop Llc Microporous rare earth silicates and method of producing same
US6596254B1 (en) 2000-06-12 2003-07-22 Sandia Corporation Niobate-based octahedral molecular sieves
AU2002242103A1 (en) 2001-02-06 2002-08-19 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
US6814871B1 (en) 2001-07-13 2004-11-09 Uop Llc Process for removing pollutants from aqueous streams
US6689335B1 (en) 2002-12-19 2004-02-10 Eastman Kodak Company Silver ion sequester and release agent
KR100804360B1 (ko) 2003-12-15 2008-02-15 아사히 가세이 케미칼즈 가부시키가이샤 다공성 성형체 및 그의 제조 방법
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
EP1732523B9 (en) 2004-03-30 2010-06-02 Relypsa, Inc. Potassium binding polymers and uses thereof
CA2733189C (en) 2004-12-28 2013-06-04 Renal Solutions, Inc. Method of synthesizing zirconium phosphate particles
US7967984B2 (en) 2005-06-14 2011-06-28 Asahi Kasei Chemicals Corporation Apparatus for water treatment and method of treating water
DE112006002618T5 (de) 2005-09-30 2008-08-28 Ilypsa Inc., Santa Clara Verfahren und Zusammensetzungen zum selektiven Entfernen von Kaliumionen aus dem Gastrointestinaltrakt eines Säugers
US8586097B2 (en) 2005-09-30 2013-11-19 Relypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
US7201885B1 (en) * 2005-11-17 2007-04-10 J.M. Huber Corporation Method of removing heavy metals from silicate sources during silicate manufacturing
US7297318B2 (en) * 2005-11-17 2007-11-20 J.M. Huber Corporation Method of removing heavy metals from silicate sources during silicate manufacturing
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007127390A2 (en) 2006-04-28 2007-11-08 Biolife, L.L.C. Materials and methods for wound treatment
KR101002571B1 (ko) 2007-01-03 2010-12-17 주식회사 인실리코텍 다공성 금속-유기 골격 구조를 갖는 배위중합체 결정 및이의 제조방법
ES2304890B1 (es) 2007-04-03 2009-10-30 Universidad De Zaragoza Procedimiento de obtencion de esferas de titanosilicato.
CN103113022B (zh) 2008-02-26 2016-09-28 康宁股份有限公司 用于硅酸盐玻璃的澄清剂
HUE061320T2 (hu) 2008-08-22 2023-06-28 Vifor Int Ltd Térhálósított kationcserélõ polimerek, készítmények és ezek alkalmazása hiperkalémia kezelésében
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US8865121B2 (en) 2009-06-18 2014-10-21 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material
GB0913525D0 (en) * 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
US20120070468A1 (en) 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
BR112013020533A2 (pt) * 2011-02-11 2016-10-18 Zs Pharma Inc silicato de zircônio microporoso para o tratamento de hipercalemia
EP2694437B1 (en) 2011-04-08 2020-10-21 Basf Se Process for producing acylation catalyst
US9527751B2 (en) 2011-11-11 2016-12-27 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material of the CHA-type structure
WO2013118063A1 (en) 2012-02-06 2013-08-15 Basf Se Iron- and copper-containing zeolite beta from organotemplate-free synthesis and use thereof in the selective catalytic reduction of nox
US9475041B2 (en) 2012-04-24 2016-10-25 Basf Se Zeolitic materials and methods for their preparation using alkenyltrialkylammonium compounds
AU2013290141A1 (en) * 2012-07-11 2015-02-05 Alvaro F. Guillem Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
US8877255B2 (en) 2012-10-22 2014-11-04 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
EP2981272B1 (en) * 2013-04-05 2023-03-01 ZS Pharma, Inc Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
KR102332954B1 (ko) * 2013-11-08 2021-11-29 제트에스 파마, 인코포레이티드 고칼륨혈증의 치료를 위한 미세다공성 규산지르코늄
KR20160096178A (ko) * 2013-12-10 2016-08-12 제트에스 파마, 인코포레이티드 리튬 공동 투여 없이 고칼륨혈증을 치료하기 위한 규산지르코늄
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof

Also Published As

Publication number Publication date
CL2018000916A1 (es) 2018-08-17
US11738044B2 (en) 2023-08-29
CN113143958A (zh) 2021-07-23
US20190365800A1 (en) 2019-12-05
HK1254808A1 (zh) 2019-07-26
AU2016338753A1 (en) 2018-04-12
TWI742004B (zh) 2021-10-11
PH12018500786B1 (en) 2022-09-07
CA3000950C (en) 2023-10-31
PH12018500786A1 (en) 2018-10-29
IL258478B (en) 2020-09-30
ZA201803095B (en) 2019-11-27
US9592253B1 (en) 2017-03-14
MX2018004440A (es) 2018-07-06
EP3362456A4 (en) 2019-05-15
AU2016338753C1 (en) 2019-08-08
NZ740931A (en) 2024-12-20
US10300087B2 (en) 2019-05-28
WO2017066128A1 (en) 2017-04-20
JP2018530596A (ja) 2018-10-18
CA3000950A1 (en) 2017-04-20
KR20180067614A (ko) 2018-06-20
MY187088A (en) 2021-08-30
KR102667566B1 (ko) 2024-05-22
CN108137620B (zh) 2021-05-18
TW201717972A (zh) 2017-06-01
EA201890875A1 (ru) 2018-11-30
BR112018007189A2 (pt) 2018-10-16
EA035890B1 (ru) 2020-08-27
AU2016338753B2 (en) 2019-04-18
US20170151279A1 (en) 2017-06-01
CN108137620A (zh) 2018-06-08
US20240009229A1 (en) 2024-01-11
CR20180276A (es) 2018-09-19
IL258478A (en) 2018-05-31
EA202091273A1 (ru) 2021-02-03
JP6546700B2 (ja) 2019-07-17
EP3362456A1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
AR106369A1 (es) Uso prolongado de composiciones de silicato de circonio y métodos para su uso
MX2017001512A (es) Compuestos activos hacia bromodominios.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2014002915A1 (es) Compuestos derivados de imidazotiadiazol e imidazopirazina, como inhibidores del receptor activado de proteasa 4 (par4); composicion farmaceutica que los comprende; y su uso para inhibir o prevenir la agregacion plaquetaria y por lo tanto utiles en el tratamiento de un trastorno tromboembolico o para la profilaxis primaria o secundaria de un trastorno tromboembolico.
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
PE20151759A1 (es) Imidazopiridazinas sustituidas
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
BR112018004243A2 (pt) misturas biocidas
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
AR099209A1 (es) Lignina en polvo
MX2017014128A (es) 2-tiopirimidinonas.
AR099285A1 (es) Polieteraminas secundarias como inhibidores de hidratos del gas natural, en bajas dosis
AR097111A1 (es) Combinación y método para la administración a un animal
CL2016002653A1 (es) Combinación farmacéutica que comprende brexpiprazol y nalmefeno; composición farmacéutica que los comprende; kit farmacéutico; y uso de la combinación para la prevención y tratamiento de un trastorno relacionado con sustancias como el alcohol.
CL2013000835A1 (es) Compuestos derivados de metilciclohexano, moduladores del oxido nitrico; composicion farmaceutica que los comprende y su uso en el tratamiento y/o profilaxis del dolor cronico o agudo.
AR099750A1 (es) COMPOSICIONES PARA LA PREVENCIÓN Y/O EL TRATAMIENTO DE PATOLOGÍAS RELACIONADAS CON LA a-GLUCOSIDASA
CL2015002681A1 (es) Formulación de dosificación oral solida del inhibidor de hcv en estado amorfo

Legal Events

Date Code Title Description
FG Grant, registration